Finance

Lists
Q3 2026 earnings • in 2 days
See details
USPH:NYSE
US Physical Therapy Inc
USD 84,90
-0,06%
(-0,050) 1D
2 Nov., 16:00:03 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for USPH...
Mkt. cap
1,27 mjd
Avg. vol.
171,48 k
Volume
0,00
Dividend
2,17%
Quarterly dividend
USD 0,46
Ex-dividend date
21 Aug. 2026
P/E ratio
483,10
52-wk high
USD 90,94
52-wk low
USD 58,19
EPS
USD 0,18
Beta
1,16
Shares outstanding
14,92 m
No. of employees
6 k
Mkt. cap
1,27 mjd
Avg. vol.
171,48 k
Volume
0,00
Dividend
2,17%
Quarterly dividend
USD 0,46
Ex-dividend date
21 Aug. 2026
P/E ratio
483,10
52-wk high
USD 90,94
52-wk low
USD 58,19
EPS
USD 0,18
Beta
1,16
Shares outstanding
14,92 m
No. of employees
6 k
News stories
From web sources and news partners
About US Physical Therapy Inc
CEO-
Employees6,37 k
Founded1990
HeadquartersHouston, Texas, Verenigde State van Amerika
SectorHealth care provider
Websiteusph.com
Analyst ratings
Based on 4 analysts giving stock ratings to USPH in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for USPH in the last 3 months.
Highest
Current USD 84,90
USD 98,00 (+15,43%)
Average
USD 93,67 (+10,33%)
Lowest
USD 88,00 (+3,65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Petusky
Barrington
Buy
Maintained
USD 98,00
+15,4%
10/23/2026
Benjamin Rossi
J.P. Morgan
Buy
Maintained
USD 95,00
+11,9%
09/11/2026
Jared Haase
William Blair
Hold
Reiterated
-
-
08/14/2026
Joanna Gajuk
Bank of America Securities
Buy
Reiterated
USD 88,00
+3,7%
08/06/2026
Constantine Davides
Citizens JMP
Buy
Maintained
USD 98,00
+15,4%
05/08/2026
Jack Slevin
Jefferies
Buy
Reiterated
USD 102,00
+20,1%
03/09/2026
Next call oor 2 dae
Do. 5 Nov., 17:30
Fiscal period
Q3 2026
- / USD 0,73
Revenue / Est. (USD)
- / 214,54 m
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
195,06 m
201,00 m
196,28 m
211,94 m
Cost of goods sold
152,73 m
156,58 m
157,94 m
164,37 m
Cost of revenue
152,73 m
156,58 m
157,94 m
164,37 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17,41 m
18,12 m
18,27 m
18,37 m
Operating expense
22,91 m
22,41 m
23,93 m
23,99 m
Total operating expenses
175,64 m
178,99 m
181,87 m
188,36 m
Operating income
19,42 m
22,01 m
14,41 m
23,58 m
Other non operating income
-441,00 k
198,00 k
494,00 k
7,00 k
EBT including unusual items
22,88 m
14,96 m
10,56 m
19,05 m
EBT excluding unusual items
16,96 m
20,20 m
12,49 m
20,81 m
Income tax expense
5,23 m
5,78 m
2,41 m
4,16 m
Effective tax rate
22,88%
38,66%
22,79%
21,81%
Other operating expenses
-
-
-
-
Net income
13,14 m
4,15 m
5,04 m
9,90 m
Net profit margin
6,74%
2,07%
2,57%
4,67%
Earnings per share
0,66
0,67
0,46
0,75
Interest and investment income
33,00 k
20,00 k
16,00 k
29,00 k
Interest expense
-2,41 m
-2,35 m
-2,79 m
-3,21 m
Net interest expenses
-2,38 m
-2,33 m
-2,78 m
-3,18 m
Depreciation and amortization charges
5,50 m
4,28 m
5,66 m
5,62 m
EBITDA
25,25 m
26,64 m
20,41 m
29,52 m
Gain or loss from assets sale
-18,00 k
-37,00 k
99,00 k
203,00 k
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme